Obesity Overweight clinical trials

Explore recruiting obesity overweight clinical trials.

Recruiting obesity overweight studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Obesity Overweight trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

I8F-MC-GPHJ: A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 mg in Adults Who Have Obesity or Overweight with Weight-Related Comorbidities

Germany, Belgium, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

J4M-MC-PWMP: A Master Protocol for a Randomized, Controlled, Clinical Platform Trial to Investigate the Efficacy and Safety of Interventions for Chronic Weight Management in Pediatric Participants with Obesity or Overweight (ADVANCE) J4M-MC-PW01: Efficacy, Safety, and Pharmacokinetics of Orforglipron Once Daily Oral versus Placebo in Adolescent Participants Who Have Obesity, or Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind Trial (ADVANCE-ATTAIN-ADOLESCENTS)

Poland, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATX304

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

J2A-MC-GZPO: A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared with Placebo in Participants with Obesity or Overweight with and without Type 2 Diabetes. J2A-MC-GZP1: Participants with obesity or overweight with at least 1 weight-related comorbidity, without type 2 diabetes. J2A-MC-GZP2: Participants with obesity or overweight with type 2 diabetes

Czechia, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Obesity Overweight trials by city

Obesity Overweight in Toronto Obesity Overweight in Vancouver Obesity Overweight in Montreal Obesity Overweight in Calgary Obesity Overweight in Edmonton Obesity Overweight in Ottawa Obesity Overweight in Winnipeg Obesity Overweight in Quebec City Obesity Overweight in Hamilton Obesity Overweight in Kitchener Obesity Overweight in London Obesity Overweight in Halifax Obesity Overweight in New York Obesity Overweight in Los Angeles Obesity Overweight in Chicago Obesity Overweight in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease